- Home
- LXRX vs SVRA Comparison
LXRX vs SVRA Comparison
Compare LXRX & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- SVRA
- Stock Information
- Founded
- LXRX 1995
- SVRA N/A
- Country
- LXRX United States
- SVRA United States
- Employees
- LXRX N/A
- SVRA N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- LXRX Health Care
- SVRA Health Care
- Exchange
- LXRX Nasdaq
- SVRA Nasdaq
- Market Cap
- LXRX 650.7M
- SVRA 739.1M
- IPO Year
- LXRX 2000
- SVRA N/A
- Fundamental
- Price
- LXRX $0.98
- SVRA $2.98
- Analyst Decision
- LXRX Buy
- SVRA Buy
- Analyst Count
- LXRX 2
- SVRA 6
- Target Price
- LXRX $6.00
- SVRA $10.17
- AVG Volume (30 Days)
- LXRX 4.3M
- SVRA 1.6M
- Earning Date
- LXRX 11-12-2024
- SVRA 11-12-2024
- Dividend Yield
- LXRX N/A
- SVRA N/A
- EPS Growth
- LXRX N/A
- SVRA N/A
- EPS
- LXRX N/A
- SVRA N/A
- Revenue
- LXRX $5,229,000.00
- SVRA N/A
- Revenue This Year
- LXRX $1,212.46
- SVRA N/A
- Revenue Next Year
- LXRX $219.10
- SVRA N/A
- P/E Ratio
- LXRX N/A
- SVRA N/A
- Revenue Growth
- LXRX 886.60
- SVRA N/A
- 52 Week Low
- LXRX $0.97
- SVRA $2.83
- 52 Week High
- LXRX $3.73
- SVRA $5.70
- Technical
- Relative Strength Index (RSI)
- LXRX 25.78
- SVRA 31.47
- Support Level
- LXRX $1.01
- SVRA $3.50
- Resistance Level
- LXRX $1.35
- SVRA $4.30
- Average True Range (ATR)
- LXRX 0.12
- SVRA 0.29
- MACD
- LXRX -0.06
- SVRA -0.05
- Stochastic Oscillator
- LXRX 0.43
- SVRA 10.24
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.